Researcher.Life Logo

Microbial Drug Resistance : Impact Factor & More

eISSN: 1931-8448pISSN: 1076-6294

Key Metrics

CiteScore
5.7
H-Index
75
Impact Factor
< 5
SJR
Q2Immunology
SNIP
0.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Microbial Drug Resistance

Microbial Drug Resistance Journal Specifications

Overview
Publisher MARY ANN LIEBERT, INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1995
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Microbial Drug Resistance ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Microbial Drug Resistance

Emergence of Teicoplanin and Linezolid Resistance in Clinical Isolates of Methicillin-Resistant and -Susceptible Staphylococcus aureus.
  • 1 Jun 2026
  • Microbial drug resistance (Larchmont, N.Y.)
A Multicenter Surveillance of Antimicrobial Resistance Among Pseudomonas aeruginosa in Hospitals of the Greater Accra Region of Ghana.
  • 1 Jun 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Early Transition to Oral Levonadifloxacin in Two Divergent Staphylococcal Infections: Integrating Features of Levonadifloxacin and Evidence from POET and OVIVA Trials.
  • 13 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Persistence of MCR-1-Positive Colistin-Resistant E. coli ST162, ST93, and ST3941 Clones in Poultry Farms, Algeria.
  • 12 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli from Community Fecal Samples in Sivas, Türkiye: Detection of the ST131 Clone.
  • 8 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Clinical Outcomes of High-Dose Ampicillin-Sulbactam Combined with Colistin in the Treatment of Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii.
  • 8 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Emergence of Teicoplanin and Linezolid Resistance in Clinical Isolates of Methicillin-Resistant and -Susceptible Staphylococcus aureus.
  • 1 Jun 2026
  • Microbial drug resistance (Larchmont, N.Y.)
A Multicenter Surveillance of Antimicrobial Resistance Among Pseudomonas aeruginosa in Hospitals of the Greater Accra Region of Ghana.
  • 1 Jun 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Early Transition to Oral Levonadifloxacin in Two Divergent Staphylococcal Infections: Integrating Features of Levonadifloxacin and Evidence from POET and OVIVA Trials.
  • 13 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Persistence of MCR-1-Positive Colistin-Resistant E. coli ST162, ST93, and ST3941 Clones in Poultry Farms, Algeria.
  • 12 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli from Community Fecal Samples in Sivas, Türkiye: Detection of the ST131 Clone.
  • 8 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)
Clinical Outcomes of High-Dose Ampicillin-Sulbactam Combined with Colistin in the Treatment of Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii.
  • 8 May 2026
  • Microbial drug resistance (Larchmont, N.Y.)

FAQs on Microbial Drug Resistance